Clinical Trial Update: Study to Evaluate the Safety and Effectiveness of Zostavax™ in Subjects 50 - 59 Years of Age (V211-022) [Phase 3]

View source ↗

Summary

A Phase 3 study evaluated the safety and effectiveness of the Zostavax shingles vaccine in adults aged 50-59; the trial is completed and results were posted in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Herpes Zoster

Drugs mentioned

• Zostavax (Varicella zoster vaccine live)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Shingles | Phase 3 | Status: COMPLETED | Results posted: 2011-05-02